Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
08 August 2006Website:
http://www.cytosorbents.comNext earnings report:
01 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 02 Jul 2024 23:45:15 GMTDividend
Analysts recommendations
Institutional Ownership
CTSO Latest News
PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that on June 28, 2024, the Company entered into a new $20 million credit facility with Avenue Capital Group, including its Avenue Venture Opportunities Fund, L.P.
CytoSorbents Corporation (CTSO) Q4 2023 Earnings Call Transcript
Cytosorbents Corporation (CTSO) Q3 2023 Earnings Call Transcript
Cytosorbents Corporation. (NASDAQ:CTSO ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Taylor Devlin - Revenue Accountant Phillip Chan - Chief Executive Officer Vincent Capponi - President and Chief Operating Officer Kathleen Bloch - Interim Chief Financial Officer Efthymios Deliargyris - Chief Medical Officer Christopher Cramer - Senior Vice President of Business Development Irina Kulinets - Senior Vice President of Regulatory Conference Call Participants Joshua Jennings - TD Cowen Laura Suriel - Alliance Global Partners Sean Lee - H.C.
Cytosorbents Corporation (NASDAQ:CTSO ) Q1 2023 Results Earnings Conference Call May 2, 2023 4:30 AM ET Company Participants Taylor Devlin - Revenue Accountant Phillip Chan - Chief Executive Officer Kathleen Bloch - Interim Chief Financial Officer Efthymios Deliargyris - Chief Medical Officer Christian Steiner - Executive Vice President of Sales and Marketing Conference Call Participants Thomas Kerr - Zacks Investment Research Sean Lee - H.C. Wainwright & Co. Operator Good afternoon and welcome to the Cytosorbents First Quarter 2023 Financial and Operating Results Conference Call.
What type of business is Cytosorbents?
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
What sector is Cytosorbents in?
Cytosorbents is in the Healthcare sector
What industry is Cytosorbents in?
Cytosorbents is in the Medical Devices industry
What country is Cytosorbents from?
Cytosorbents is headquartered in United States
When did Cytosorbents go public?
Cytosorbents initial public offering (IPO) was on 08 August 2006
What is Cytosorbents website?
https://www.cytosorbents.com
Is Cytosorbents in the S&P 500?
No, Cytosorbents is not included in the S&P 500 index
Is Cytosorbents in the NASDAQ 100?
No, Cytosorbents is not included in the NASDAQ 100 index
Is Cytosorbents in the Dow Jones?
No, Cytosorbents is not included in the Dow Jones index
When does Cytosorbents report earnings?
The next expected earnings date for Cytosorbents is 01 August 2024